Genital Warts Treatment Market, By Drug Type (Imiquimod, Podophyllin and Podofilox, Trichloroacetic Acid, Sinecatechins, Others), By Route of Administration (Parenteral and Topical), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Published In : Feb 2025

Code : CMI4534

Pages :149

Formats :

Excel and PDF

Industry : Pharmaceutical

Genital Warts Treatment Market Size and Trends

Global genital warts treatment market is estimated to be valued at USD 2.01 Bn in 2025 and is expected to reach USD 2.91 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 5.4% from 2025 to 2032.

Genital Warts Treatment Market Key Factors

To learn more about this report, Request sample copy

Increasing awareness among people about sexually transmitted diseases and availability of effective drugs and medicines for treatment of genital warts can drive the market growth. Developing healthcare infrastructure in emerging nations can also boost demand for genital warts treatment. However, social stigma associated with the condition and preference of patients towards non-drug therapies can hamper the market growth. Increasing awareness campaigns by governments and non-profit organizations as well as development of novel treatment therapies can offer new opportunities for the players in the global genital warts treatment market during the forecast period.

Rising prevalence of HPV infections

Increasing prevalence of HPV infections across both developed and developing regions can drive the genital warts treatment market growth. HPV, or human papillomavirus, is the most common STI globally and a leading cause of genital warts. Several strains of HPV are known to cause genital warts, with types 6 and 11 being the predominant strains associated with wart development. As per medical experts, HPV infection rates have surged in recent decades due to changing sexual behaviors such as early initiation of sexual activity, multiple sexual partners, and lack of protective barriers. Moreover, diagnosis of HPV infection has become more efficient with new diagnostic tools broadening the potential patient pool. At least 80% of sexually active individuals can acquire HPV infection at some point in their lives. Individuals with compromised immunity are at higher risk of getting infected. While many HPV infections resolve on their own, a substantial fraction of infected individuals develop visible genital warts that require medical intervention. Since there is no cure for HPV itself, the long-term treatment of recurring symptoms can boost repeat usage of wart remover therapies and surgical procedures. Significant monetary investments are also being made towards HPV vaccination but it will be many years before their effect in reducing transmission becomes evident.